Navigation Links
Advanced Cell Technology Develops First Human Embryonic Stem Cell,Line without Destroying an Embryo

ALAMEDA, Calif.--(BUSINESS WIRE)--Jun 21, 2007 - Advanced Cell Technology, Inc. (OTCBB: ACTC) has successfully produced a human embryonic stem cell (hESC) line without destroying an embryo at its lab in Worcester, Massachusetts. This development was announced by Robert Lanza, M.D., V.P. of Research and Scientific Development of Advanced Cell Technology (ACT) on Tuesday at the fifth annual meeting of the International Society for Stem Cell Research (ISSCR) in Cairns, Australia.

In August 2006, ACT published a paper in Nature Magazine documenting a technique for removing a single cell (known as a blastomere) from an eight-cell human embryo, and using that cell to generate multiple hESCs without destroying the embryo.

At the ISSCR meeting, Dr. Lanza definitively announced that he and his team have now reproduced the work of removing a single cell blastomere from a human embryo with the surviving embryo cryo-preserved. Dr. Lanza noted at the meeting, "These are the first human embryonic stem cells in existence to be made without destroying an embryo."

This development comes on the heels of President Bush's veto of federal legislation which would have provided funding for embryonic stem cell research.

In an appearance yesterday on Bloomberg Television's "On the Economy," juxtaposed with the President's press conference relating to his stem cell funding veto, William M. Caldwell, IV, Chairman and CEO of ACT, commented on ACT's single cell blastomere development: "It does address the President's concern. We're very excited about this technology, and we're using it today to develop treatments for (addressing) macular degeneration."

Today Mr. Caldwell said, "The American people spoke through their representatives in Congress when federal funding legislation was passed by both houses and presented to the President. We are, of course, very disappointed with his veto yesterday. Our single cell b lastomere technology directly addresses the President's ethical concerns and is available today, unlike the science projects announced by the President yesterday. Despite the veto, and particularly in light of this new advance, we call on the National Institutes of Health to reflect the will of the American people and approve funding for research applications of our single cell blastomere technology."

A streaming video of the interview will be accessible later today on Advanced Cell's website by clicking here: http://www.advancedcell.com/media-gallery/.

Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.

For more information, visit www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on pot ential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Contact

The Investor Relations Group
Investors:
James Carbonara or Joseph Kessler, 212-825-3210
or
Media:
Bill Douglass, 212-825-3210


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016  This month,s issue of the Journal ... an in-depth look at various causes and consequences associated with rising ... spending, which has generated significant public outrage and calls ... Laura E. Happe , PharmD, MPH. --> ... MPH. --> In 2014 prescription drug spending ...
(Date:2/12/2016)... -- Innophos Holdings, Inc. (NASDAQ: IPHS ), a leading international ... it will host a live conference call on Tuesday, February ... quarter and full year 2015 results. ... quarter and full year results will be issued on Monday, ... --> --> The conference call can be ...
(Date:2/12/2016)... , Feb. 12, 2016   HeartWare International, Inc ... call and webcast to discuss its financial results for ... on Thursday, February 25, 2016 at 8:00 a.m. ET. ... to the conference call and webcast.  On the conference ... results, highlights from the fourth quarter and business outlook.   ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, owner Tal Rabinowitz ... no time to decompress, Rabinowitz found herself drawn to a casual meditation class while ... on her life, implementing a 20-minute-per-day meditation practice with her team. After her tenure ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a leader in cloud ... Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. ... their small and medium business (SMB) clients. , In recent years, ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a ... across eastern Texas, is launching a cooperative charity drive with the Tarrant Area Food ... more than 50,000 individuals and families in need, the Tarrant County Food Bank offers ...
(Date:2/12/2016)... ... 12, 2016 , ... Donor Network West, the organ procurement organization that heals ... with San Ramon Regional Medical Center. Under the collaboration, the first of its kind, ... accommodate a more certain time frame for donor families for the recovery of organs. ...
(Date:2/12/2016)... NY (PRWEB) , ... February 12, 2016 , ... ... of “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer ... Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately ...
Breaking Medicine News(10 mins):